PGP and chronic myelogenous leukemia, BCR-ABL1 positive: K562/ADM, a P-gp-overexpressed adriamycin resistant CML cell line, shows resistance not only to adriamycin itself, but also to a broad range of anticancer reagents, including vincristine, etoposide and the one line CML chemotherapeutic drug imatinib [27, 28].